BUZZ-Hims & Hers slides after it forecasts Q1 revenue below estimates

Reuters02-24 17:44

BUZZ-Hims & Hers slides after it forecasts Q1 revenue below estimates

** Shares of online telehealth company Hims & Hers Health HIMS.N fall 6.7% to $15.51 in premarket trading

** Co on Monday forecast Q1 revenue below estimates, citing a $65 million hit from changes in the shipping of weight-loss products for personalized prescriptions

** HIMS, which grew rapidly after it offered cheaper compounds of weight-loss drugs, now expects Q1 revenue in the range of $600 million to $625 million, below estimates of $653.11 million, according to data compiled by LSEG

** Morningstar sees several uncertainties for HIMS, including the Novo Nordisk litigation, regulatory risks around compounding, and execution risk for new launches and markets

** Earlier this month, the FDA said it would take action against HIMS for its $49 copycat weight-loss pill; co was also referred to the Dept of Justice for violation

** 16 analysts rate the stock "hold" on average; median PT is $22 - data compiled by LSEG

** As of last close, stock down 52.23% YTD

(Reporting by Kanishka Ajmera in Bengaluru)

((mail to: Kanishka.Ajmera@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613879172?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 17:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613879172","market":"us","top_or_hot":-1,"title":"BUZZ-Hims & Hers slides after it forecasts Q1 revenue below estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Hims &amp; Hers slides after it forecasts Q1 revenue below estimates</title></head><body><p>   ** Shares of online telehealth company Hims &amp; Hers Health <span>HIMS.N</span> fall 6.7% to $15.51 in premarket trading</p><p>** Co on Monday forecast Q1 <span>revenue below estimates</span>, citing a $65 million hit from changes in the shipping of weight-loss products for personalized prescriptions</p><p>** HIMS, which grew rapidly after it offered cheaper compounds of weight-loss drugs, now expects Q1 revenue in the range of $600 million to $625 million, below estimates of $653.11 million, according to data compiled by LSEG</p><p>** Morningstar sees several uncertainties for HIMS, including the <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> <span>litigation</span>, regulatory risks around compounding, and execution risk for new launches and markets</p><p>        ** Earlier this month, the FDA said it would take action against HIMS for its $49 copycat weight-loss pill; co was also referred to the Dept of Justice for violation</p><p>** 16 analysts rate the stock \"hold\" on average; median PT is $22 - data compiled by LSEG</p><p>** As of last close, stock down 52.23% YTD</p><p> (Reporting by Kanishka Ajmera in Bengaluru)</p><p> ((mail to: Kanishka.Ajmera@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Hims & Hers slides after it forecasts Q1 revenue below estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Hims & Hers slides after it forecasts Q1 revenue below estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-24 17:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Hims &amp; Hers slides after it forecasts Q1 revenue below estimates</title></head><body><p>   ** Shares of online telehealth company Hims &amp; Hers Health <span>HIMS.N</span> fall 6.7% to $15.51 in premarket trading</p><p>** Co on Monday forecast Q1 <span>revenue below estimates</span>, citing a $65 million hit from changes in the shipping of weight-loss products for personalized prescriptions</p><p>** HIMS, which grew rapidly after it offered cheaper compounds of weight-loss drugs, now expects Q1 revenue in the range of $600 million to $625 million, below estimates of $653.11 million, according to data compiled by LSEG</p><p>** Morningstar sees several uncertainties for HIMS, including the <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> <span>litigation</span>, regulatory risks around compounding, and execution risk for new launches and markets</p><p>        ** Earlier this month, the FDA said it would take action against HIMS for its $49 copycat weight-loss pill; co was also referred to the Dept of Justice for violation</p><p>** 16 analysts rate the stock \"hold\" on average; median PT is $22 - data compiled by LSEG</p><p>** As of last close, stock down 52.23% YTD</p><p> (Reporting by Kanishka Ajmera in Bengaluru)</p><p> ((mail to: Kanishka.Ajmera@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL6N3ZK0LC:1","article_id":"2613879172","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613879172","pubTimestamp":1771926269,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Hims & Hers slides after it forecasts Q1 revenue below estimates   ** Shares of online telehealth company Hims & Hers Health HIMS.N fall 6.7% to $15.51 in premarket trading** Co on Monday forecast Q1 revenue below estimates, citing a $65 million hit from changes in the shipping of weight-loss products for personalized prescriptions** HIMS, which grew rapidly after it offered cheaper compounds of weight-loss drugs, now expects Q1 revenue in the range of $600 million to $625 million, below estimates of $653.11 million, according to data compiled by LSEG** Morningstar sees several uncertainties for HIMS, including the Novo Nordisk litigation, regulatory risks around compounding, and execution risk for new launches and markets        ** Earlier this month, the FDA said it would take action against HIMS for its $49 copycat weight-loss pill; co was also referred to the Dept of Justice for violation** 16 analysts rate the stock \"hold\" on average; median PT is $22 - data compiled by LSEG*","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc.","HMYY":"GraniteShares YieldBoost HIMS ETF","HIMZ":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","BK4196":"保健护理服务","HIYY":"YieldMax HIMS Option Income Strategy ETF","HIMY":"Defiance Leveraged Long + Income HIMS ETF"},"translate_title":"BUZZ-Hims&Hers预测第一季度收入低于预期后股价下滑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIYY":0.6,"HMYY":0.6,"HIMY":0.6,"HIMS":1.98,"HIMZ":0.6},"content_text":"BUZZ-Hims & Hers slides after it forecasts Q1 revenue below estimates   ** Shares of online telehealth company Hims & Hers Health HIMS.N fall 6.7% to $15.51 in premarket trading** Co on Monday forecast Q1 revenue below estimates, citing a $65 million hit from changes in the shipping of weight-loss products for personalized prescriptions** HIMS, which grew rapidly after it offered cheaper compounds of weight-loss drugs, now expects Q1 revenue in the range of $600 million to $625 million, below estimates of $653.11 million, according to data compiled by LSEG** Morningstar sees several uncertainties for HIMS, including the Novo Nordisk litigation, regulatory risks around compounding, and execution risk for new launches and markets        ** Earlier this month, the FDA said it would take action against HIMS for its $49 copycat weight-loss pill; co was also referred to the Dept of Justice for violation** 16 analysts rate the stock \"hold\" on average; median PT is $22 - data compiled by LSEG** As of last close, stock down 52.23% YTD (Reporting by Kanishka Ajmera in Bengaluru) ((mail to: Kanishka.Ajmera@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613879172","isCrawlerRequest":true}